SCHEMBL2975969

SCHEMBL2975969

CCNC(=O)c1cnc2c(c1)ncn2-c1cccc(OCc2ccc(OC(F)(F)F)cc2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR132 Q9UNW8 1/20 0.43
MRGPRX4 Q96LA9 2/20 0.43
NTRK1 P04629 1/20 0.42
KCNH2 Q12809 1/20 0.42
HPGD P15428 6/20 0.42
ALDH1A1 P00352 5/20 0.42
CYP2C9 P11712 3/20 0.42
CYP2C19 P33261 3/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2D6 P10635 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
KDM4E B2RXH2 4/20 0.42
GAA P10253 1/20 0.41
CYP3A4 P08684 1/20 0.40
RXRA P19793 1/20 0.39
GRIN1 Q05586 1/20 0.39
GRIN2B Q13224 1/20 0.39
EPHX2 P34913 1/20 0.39
NR1H4 Q96RI1 1/20 0.39
MAOB P27338 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2961360 0.92 HPGD (0.44) MRGPRX4NTRK1KCNH2HPGDALDH1A1
SCHEMBL2969649 0.91 MRGPRX4 (0.44) GPR132MRGPRX4NTRK1KCNH2HPGD
SCHEMBL2973144 0.91 HPGD (0.45) GPR132MRGPRX4HPGDALDH1A1CYP2C9
SCHEMBL2975345 0.90 MAOB (0.49) GPR132MRGPRX4HPGDALDH1A1CYP2C9
SCHEMBL2966243 0.90 KMT2A (0.43) GPR132MRGPRX4HPGDCYP2C9CYP2C19
SCHEMBL4072391 0.87 MRGPRX4 (0.40) GPR132MRGPRX4HPGDALDH1A1CYP2C9
SCHEMBL2974343 0.87 LMNA (0.51) GPR132HPGDALDH1A1CYP2C9CYP2C19
SCHEMBL1377978 0.87 MAPK1 (0.52) HPGDALDH1A1CYP2C9CYP2C19CYP1A2
SCHEMBL2975296 0.83 RIPK1 (0.47) MRGPRX4NTRK1KCNH2HPGDALDH1A1
SCHEMBL2970729 0.83 HPGD (0.47) MRGPRX4HPGDALDH1A1CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7767673-B2 N-substituted imidazopyridine c-Kit inhibitors OSI PHARMACEUTICALS, INC. (US) 2010-08-03 US claimed
EP-1658289-B1 3-SUBSTITUTED IMIDAZOPYRIDINE-DERIVATIVES AS C-KIT INHIBITORS OSI PHARM INC (US) 2009-03-18 EP claimed
US-20090062275-A1 N-Substituted Imidazopyridine c-Kit Inhibitors OSI PHARMACEUTICALS, INC. 2009-03-05 US claimed
US-20080221153-A9 N3-SUBSTITUTED IMIDAZOPYRIDINE C-KIT INHIBITORS CASTELHANO ARLINDO L 2008-09-11 US claimed
JP-2007502822-A 2007-02-15 JP claimed
EP-1658289-A2 3-SUBSTITUTED IMIDAZOPYRIDINE-DERIVATIVES AS C-KIT INHIBITORS OSI Pharmaceuticals, Inc. (US) 2006-05-24 EP claimed
US-20060035921-A1 N3-substituted imidazopyridine c-Kit inhibitors CASTELHANO ARLINDO L 2006-02-16 US claimed
WO-2005021544-A2 N3-SUBSTITUTED IMIDAZOPYRIDINE-DERIVATIVES AS C-KIT INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2005-03-10 WO claimed
US-7767673-B2 N-substituted imidazopyridine c-Kit inhibitors OSI PHARMACEUTICALS, INC. (US) 2010-08-03 US disclosed
EP-1658289-B1 3-SUBSTITUTED IMIDAZOPYRIDINE-DERIVATIVES AS C-KIT INHIBITORS OSI PHARM INC (US) 2009-03-18 EP disclosed
US-20090062275-A1 N-Substituted Imidazopyridine c-Kit Inhibitors OSI PHARMACEUTICALS, INC. 2009-03-05 US disclosed
US-7442709-B2 N3-substituted imidazopyridine c-Kit inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-10-28 US disclosed
US-20080221153-A9 N3-SUBSTITUTED IMIDAZOPYRIDINE C-KIT INHIBITORS CASTELHANO ARLINDO L 2008-09-11 US disclosed
EP-1658289-A2 3-SUBSTITUTED IMIDAZOPYRIDINE-DERIVATIVES AS C-KIT INHIBITORS OSI Pharmaceuticals, Inc. (US) 2006-05-24 EP disclosed
US-20060035921-A1 N3-substituted imidazopyridine c-Kit inhibitors CASTELHANO ARLINDO L 2006-02-16 US disclosed
WO-2005021544-A2 N3-SUBSTITUTED IMIDAZOPYRIDINE-DERIVATIVES AS C-KIT INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2005-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062275-A1 N-Substituted Imidazopyridine c-Kit Inhibitors KIT, ABL1, CHUK GPR132 3167/4885MRGPRX4 1412/4885NTRK1 242/4885
US-20080221153-A9 N3-SUBSTITUTED IMIDAZOPYRIDINE C-KIT INHIBITORS KIT, ABL1, CHUK GPR132 2840/4885MRGPRX4 1252/4885NTRK1 235/4885
US-20060035921-A1 N3-substituted imidazopyridine c-Kit inhibitors KIT, ABL1, CHUK GPR132 2840/4885MRGPRX4 1252/4885NTRK1 235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.